GlaxoSmithKline
Candidate UTI vaccine low dose formulation 1
Urinary Tract Infections
Countdown
328days
Phase 2 readout · May 31, 2027
What's at stake
Phase 2 trial results for Candidate UTI vaccine low dose formulation 1 in Urinary Tract Infections are due May 31, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT06702449: Phase 2 trial, sponsor GlaxoSmithKline, drug Candidate UTI vaccine low dose formulation 1. Primary completion date 2027-05-31 (estimated).”